Emmaus Life Sciences Reports Management Changes : comparemel

Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported that on August 18, 2023 the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as Chief Executive Officer of Emmaus, or as Chairman of the Board, in order to allow Dr. Niihara to pursue business opportunities in Ube, Japan and in India previously initiated by Emmaus. Dr. Niihara was the p

Related Keywords

United States , Bahrain , United Arab Emirates , Qatar , France , Israel , Kuwait , Woman , Netherlands , Saudi Arabia , Saudi , Kingdom Of Saudi Arabia , Americans , George Sekulich , Willis Lee , Exchange Commission On , Saudi Food Drug Authority , Committee On Addressing Sickle Cell Disease , Emmaus Life Sciences , Centers For Disease , Emmaus Life Sciences Inc , Blueprint For Action National Academy Of Sciences , National Center On Birth Defects , Company Contact , Drug Administration , Chief Operating Officer , Chief Information Officer , Senior Vice President Global Commercialization , Chief Executive , Middle East North Africa , Life Sciences , Saudi Food , Prescribing Information , Sickle Cell Disease , National Center , Birth Defects , Developmental Disabilities , Disease Control , Addressing Sickle Cell Disease , Strategic Plan , Sciences Press , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Exchange Commission , Yutaka Niihara , Chief Executive Officer , Iopharmaceutical Company , Emmaus , Kendari , Gulf Cooperation Council , Nc ,